scholarly journals In vivo Treg expansion under costimulation blockade targets early rejection and improves long‐term outcome

2021 ◽  
Author(s):  
Christoph Schwarz ◽  
Benedikt Mahr ◽  
Moritz Muckenhuber ◽  
Anna Marianne Weijler ◽  
Lukas Walter Unger ◽  
...  
Keyword(s):  
Costimulation Blockade ◽  
Term Outcome ◽  
Long Term Outcome

scholarly journals Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity

2019 ◽  
Vol 3 (22) ◽  
pp. 3688-3699 ◽  
Author(s):  
Franziska Schramm ◽  
Udo zur Stadt ◽  
Martin Zimmermann ◽  
Norbert Jorch ◽  
Arnulf Pekrun ◽  
...  
Keyword(s):  
Drug Testing ◽  
Drug Response ◽  
Lymphoblastic Leukemia ◽  
Term Outcome ◽  
Childhood All ◽  
Long Term Outcome ◽  
Key Points

Key Points Report of the long-term outcome of children with acute lymphoblastic leukemia upon risk-adapted therapy accrued in trial CoALL 07-03. Lack of correlation between in vitro and in vivo drug response as well as a lower predictive value of in vitro drug testing.

Exposure in vivo vs social skills training for social phobia: Long-term outcome and differential effects

1990 ◽  
Vol 28 (3) ◽  
pp. 181-193 ◽  
Author(s):  
Zygmunt Wlazlo ◽  
Karin Schroeder-Hartwig ◽  
Iver Hand ◽  
Grazyna Kaiser ◽  
Nicole Münchau
Keyword(s):  
Social Skills ◽  
Social Phobia ◽  
Social Skills Training ◽  
Skills Training ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Differential Effects ◽  
Exposure In Vivo

Monitoring Coping Style and Exposure Outcome in Spider Phobics

1993 ◽  
Vol 21 (4) ◽  
pp. 329-333 ◽  
Author(s):  
Peter Muris ◽  
Peter de Jong ◽  
Harald Merckelbach ◽  
Florence van Zuuren
Keyword(s):  
Information Seeking ◽  
Coping Style ◽  
Coping Styles ◽  
Therapy Outcome ◽  
Short Term ◽  
Term Outcome ◽  
Long Term Outcome

The present study investigated whether information seeking coping styles (monitoring and blunting) affect exposure therapy outcome. Subjects were 33 spider phobics who received one 2.5 hours session in vivo treatment. In general, the treatment yielded good results. Coping style did not contribute substantially to short-term or long-term outcome (at 18 months follow-up).

Long-term outcome of cryopreserved bone-derived osteoblasts for bone regeneration in vivo

Biomaterials ◽  
2011 ◽  
Vol 32 (20) ◽  
pp. 4546-4555 ◽  
Author(s):  
Shaoyi Wang ◽  
Wenjie Zhang ◽  
Jun Zhao ◽  
Dongxia Ye ◽  
Chao Zhu ◽  
...  
Keyword(s):  
Bone Regeneration ◽  
Term Outcome ◽  
Long Term Outcome

scholarly journals t(12;21)/ETV6 -RUNX1 Confers a Specific Pattern of In Vivo Sensitivity to Treatments in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Trials 58881 and 58951 of the EORTC Children Leukemia Group

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 793-793
Author(s):  
Caroline Piette ◽  
Stefan Suciu ◽  
Emmanuelle Clappier ◽  
Yves Bertrand ◽  
Genevieve Plat ◽  
...  
Keyword(s):  
High Risk ◽  
Average Risk ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Free Survival ◽  
Excellent Outcome ◽  
E Coli ◽  
Very High

Background In childhood BCP-ALL, the presence of t(12;21)/ETV6 -RUNX1 defines one of the most prevalent oncogenic subgroup and is usually associated with a favorable outcome. Nevertheless, an excellent prognosis has not been reported by all collaborative groups, suggesting that the outcome of ETV6 -RUNX1 patients (pts) could be influenced by the treatment. To address this issue, the long-term outcome of ETV6 -RUNX1 pts was investigated into the EORTC 58881 and 58951 studies, with particular attention to the effect of the randomized treatments. Methods The 58881 study (1989-1998) used a BFM backbone without cranial irradiation, and aimed to compare E-Coli (Medac®) Asparaginase (A'ase) with Erwinia A'ase and to assess the value of 6-Mercaptopurine (6-MP) i.v. (1 g/m²/month) when added to classic maintenance. The subsequent 58951 study (1999-2008) used the best arm of the trial 58881, i.e. E-Coli A'ase and classic maintenance. The aims of this study were to compare dexamethasone (Dexa) (6 mg/m²/day) with prednisone (Pred) (60 mg/m²/day) during induction and maintenance; to evaluate increased number of A'ase administrations (24 vs 12) for non-very high risk pts; and to assess the value of vincristine/corticosteroid pulses during maintenance for average risk pts. Detection of ETV6 -RUNX1 by FISH and/or RT-PCR was centralized. Pts less than 1 year (yr) or with t(9;22)/BCR-ABL were excluded from the analysis. Results An ETV6 -RUNX1 was evidenced in 104/363 (28%) and 380/1493 (27%) newly diagnosed BCP-ALL pts enrolled in the 58881 and 58951 trial respectively. A majority of ETV6-RUNX1 pts were below the age of 10 yrs (93.3% in 58881 and 91.3% in 58951). The median follow-up was 11.8 yrs for the 58881 and 6.7 yrs for the 58951. In both studies, the 10-yr event-free-survival (EFS) rate was significantly higher for ETV6 -RUNX1 pts than for all BCP-ALL pts (82.5% vs 74.9% in 58881 and 90.8% vs 82.7% in 58951), and was similar to the 10-yr EFS of hyperdiploid pts. Noteworthy, very few EFS events were observed during treatment period or after 6 yrs from diagnosis. The main prognostic factors of the ETV6-RUNX1 subgroup in both studies were the white blood cell count (WBC) and the response to prephase. As shown in the table below, the analysis of the relationship between treatment modalities and outcome revealed that the in vivo drug sensitivity of ETV6-RUNX1 ALL was distinct from that of other BCP-ALL. In this subgroup, the benefit of a more potent A'ase (58881) or of intensified A'ase administrations (58951) was less pronounced as compared to other pts, and 6-MP i.v. during maintenance was particularly deleterious. Moreover, the overall benefit of vincristine/corticosteroid pulses was not observed in ETV6-RUNX1 average risk group pts, who already had an outstanding outcome. By contrast, the use of Dexa in place of Pred significantly improved the 10-yr EFS of ETV6-RUNX1 pts (95.0% vs 87.2%, hazard ratio (HR)=0.44, 95% CI 0.20-0.96) whereas no difference was observed in the remaining population (HR=1.01, 95% CI 0.77-1.33) (test for interaction: p=0.04). Table.5888158951All (n=363)ETV6-RUNX1 (n=104)Hyperdiploid (n=102)Others1 (n=155)All (n=1493)ETV6-RUNX1 (n=380)Hyperdiploid (n=484)Others1 (n=619)10-yr EFS ratesAll pts74.9%82.5%83.3%65.2%82.7%90.8%88.4%73.2%Pred ² (n=745)81.8%87.2%88.8%73.0%Dexa ² (n=748)83.6%95.0%88.0%73.5%Medac A'ase 2,3 (n=320)76.6%83.2%88.6%65.7%Other A'ase 2,3 (n=43)62.8%78.6%50.0%60.0%10-yr disease-free-survival ratesShort A'ase 4 (n=607)83.5%91.2%90.1%72.4%Long A'ase 4 (n=622)87.0%94.8%88.2%80.7%No 6-MP iv 2,5 (n=96)85.4%100%90.9%72.5%6-MP iv 2,5 (n=94)72.3%70.6%78.6%68.8%No Pulse 5,6 (n=148)87.5%96.1%88.5%71.1%Pulse 5,6 (n=153)82.8%95.1%91.3%82.3%1Others, MLL rearrangements excluded 2All risk groups 3Pts randomized or not for A'ase 4Non-very high risk pts 5Pts who started maintenance 6Average risk pts Conclusions Within the EORTC 58881 and 58951 trials, the use of Dexa rather than Pred allowed to further improved the long-term outcome for ETV6-RUNX1 pts. Our data also show that this excellent outcome can be jeopardized by slight changes in therapy, such as the addition of 6-MP i.v. to classic maintenance. Together, these results stress the importance of analyzing homogeneous oncogenetic subgroups when comparing different therapeutic schemes, to unmask specific drug effects that could be hidden when analyzing the whole group of patients. Disclosures Bertrand: ERYTECH Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees.

Transcatheter Aortic Valve Implantation

2009 ◽  
Vol 4 (4) ◽  
pp. 197-205
Author(s):  
Jian Ye ◽  
Samuel V. Lichtenstein
Keyword(s):  
High Risk ◽  
Aortic Valve ◽  
Operative Mortality ◽  
Low Risk ◽  
Term Outcome ◽  
Long Term Outcome ◽  
High Risk Patients ◽  
Risk Patients

There has been significant improvement in device designs, operative techniques, and early clinical outcomes in <5 years. Presently, there are two catheter-based bioprostheses (balloon expandable or self-expandable), which have been widely used in humans and are undergoing clinical investigations. Three approaches, including transvenous, transarterial, and transapical have been used for delivery of the catheter-based bioprostheses, and transarterial and transapical approaches have been adopted by cardiologists and cardiac surgeons worldwide. The most recent clinical results have been very encouraging and promising. With experience, 30-day operative mortality with either balloon-expandable or self-expandable bioprosthesis was reduced significantly to approximately 10% in high-risk patients. In vivo long-term durability of catheter-based bioprostheses remains unknown, and presently transcatheter procedure is limited to the cohort of high-risk patients. Expanding this new technology to low-risk patients should be done with extreme caution because conventional aortic valve replacement still provides the best long-term outcome with minimal operative mortality and morbidity in low-risk patients. Ongoing clinical trials will address many unanswered questions, such as patient selection, long-term in vivo durability, preoperative assessment, and the role of the procedures in management of valvular diseases.

Favourable Long-Term Outcome after Matched Sibling Transplantation for Fanconi-Anemia (FA) and in vivo T-Cell Depletion

2008 ◽  
Vol 220 (3) ◽  
pp. 147-152 ◽  
Author(s):  
K. Huck ◽  
H. Hanenberg ◽  
W. Nürnberger ◽  
D. Dilloo ◽  
S. Burdach ◽  
...  
Keyword(s):  
T Cell ◽  
Fanconi Anemia ◽  
Cell Depletion ◽  
Term Outcome ◽  
T Cell Depletion ◽  
Long Term Outcome ◽  
Matched Sibling

scholarly journals Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene

Blood ◽  
2014 ◽  
Vol 123 (25) ◽  
pp. 3895-3905 ◽  
Author(s):  
Xiaoou Zhou ◽  
Antonio Di Stasi ◽  
Siok-Keen Tey ◽  
Robert A. Krance ◽  
Caridad Martinez ◽  
...  
Keyword(s):  
T Cells ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Immune Recovery ◽  
Caspase 9 ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Key Points

Key PointsAllodepleted-T-cells containing the iC9 safety gene persist long-term in vivo, promote immune recovery, and protect against infections. GvHD caused by iC9-T cells can be permanently controlled by a single administration of AP1903 without abrogating immune reconstitution.

Sign in / Sign up

Export Citation Format

Share Document